Myomo, Inc. reported strong financial results for the first quarter of 2025, with revenue increasing by 162% to $9.8 million. The company also saw a record number of new candidates added to its patient pipeline, despite challenges from Medicare Advantage plans and social media algorithm changes.
Revenue for Q1 2025 was $9.8 million, a 162% increase compared to Q1 2024.
The company reported a net loss of $3.465 million, or $0.08 per share, for Q1 2025.
A record 700 new candidates were added to the patient pipeline, increasing the total pipeline to 1,482 candidates.
Gross margin improved to 67.2% in Q1 2025, up 600 basis points from the previous year.
Myomo expects second quarter revenue to be between $9.0 million and $9.5 million, and full-year 2025 revenue to be in the range of $50 million to $53 million, representing a significant increase over 2024.